|
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 3.9
|
37275957
|
Zaragoza-Huesca D, Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Pena-Garcia J, Espin S, Ricote G, Nieto A, Garcia-Molina F, Vicente V, Lozano ML, Carmona-Bayonas A, Mulero V, Perez-Sanchez H, Martinez-Martinez I. Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin. Biomed Pharmacother. 2023 Dec;168:115814. doi: 10.1016/j.biopha.2023.115814. Epub 2023 Oct 31. PubMed PMID: 37918256.
AÑO: 2023; IF: 6.9
|
|
Perez-Wert P, Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Lecumberri A, Cacho Lavin D, Losantos Garcia I, Fernandez Montes A, Cano JM, Limon ML, Hernandez San Gil R, Diez M, Vidal Tocino R, Macias Declara I, Visa L, Pimentel Caceres P, Gil Raga M, Martinez Moreno E, Sauri T, Martin Richard M, Granja M, Cerda P, Gomez Gonzalez L, Merida-Garcia A, Ruiz Martin M, Gallego J; AGAMENON-SEOM study group. Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry. Gastric Cancer. 2024 Jan;27(1):131-145. doi: 10.1007/s10120-023-01443-9. Epub 2023 Nov 15. PubMed PMID: 37964032.
AÑO: 2024; IF: 5.1
|
|
Velasco-Durantez V, Cruz-Castellanos P, Hernandez R, Rodriguez-Gonzalez A, Fernandez Montes A, Gallego A, Manzano-Fernandez A, Sorribes E, Zafra M, Carmona-Bayonas A, Calderon C, Jimenez-Fonseca P. Prospective study of predictors for anxiety, depression, and somatization in a sample of 1807 cancer patients. Sci Rep. 2024 Feb 7;14(1):3188. doi: 10.1038/s41598-024-53212-y. PubMed PMID: 38326426; PubMed Central PMCID: PMC10850144.
AÑO: 2024; IF: 3.9
|
|
Muniz-Castrillo M, Blaya Boluda N, Garcia-Torralba E, Jimenez-Fonseca P, Gonzalez Del Rey C, Balbin M, Luengo-Gil G, Ayala de la Pena F, Esteban Gonzalez E, Carmona-Bayonas A. Dysfunctional mismatch repair in patients with early triple-negative breast cancer. Clin Transl Oncol. 2025 May 4. doi: 10.1007/s12094-025-03933-x. Online ahead of print. PubMed PMID: 40319412.
AÑO: 2025; IF: 2.5
|